Bolt Biotherapeutics reports Q2 2026 results, initial BDC-4182 data expected in Q3
Bolt said its Phase 1/2 trial of BDC-4182 in gastric and gastroesophageal cancer continues to enroll, with initial clinical data due alongside third-quarter results.
SEC filing